Travere Therapeutics (TVTX) Gets a Buy Rating from SVB Securities

In a report issued on August 3, Joseph Schwartz from SVB Securities maintained a Buy rating on Travere Therapeutics (TVTXResearch Report). The company’s shares closed last Thursday at $25.79.

According to, Schwartz is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -12.1% and a 34.8% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Applied Molecular Transport, Mereo Biopharma Group Plc, and Crinetics Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Travere Therapeutics with a $41.75 average price target, implying an 89.8% upside from current levels. In a report issued on July 26, Piper Sandler also maintained a Buy rating on the stock with a $41.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $31.65 and a one-year low of $13.61. Currently, Travere Therapeutics has an average volume of 811.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Retrophin, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. Its products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 8, 2008 and is headquartered in San Diego, CA.

Read More on TVTX:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More